



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms N Boota
UNIVERSITY OF WARWICK
WARWICK CLINICAL TRIALS UNIT, WARWICK MEDICAL SCHOOL, GIBBET HILL ROAD, COVENTRY,
CV4 7AL, UNITED KINGDOM

26/02/2020

Dear Ms N Boota,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 16719/0231/001-0005
Eudract Number:	2017-001785-14
Product:	Landiolol hydrochloride 300 mg lyophilised powder
Protocol number:	RRK5911
Substantial Amendment Code Number:	Code Number: SA_14 Version: Date: 2020/02/04

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 20/02/2020.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**